NCT00961324View on ClinicalTrials.gov

A Trial Investigating the Within-subject Variability of NN1250 in Subjects With Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

July 27, 2009

Primary Completion Date

October 26, 2009

Study Completion Date

October 26, 2009

Conditions
DiabetesDiabetes Mellitus, Type 1
Interventions
DRUG

insulin degludec

The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days

DRUG

insulin glargine

The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days

Trial Locations (1)

41460

Novo Nordisk Investigational Site, Neuss

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY